Rapport Therapeutics rises 9% as insiders keep buying
- Insider
- Steven M Paul
- Company
- Rapport Therapeutics (RAPP)
- Transaction
- Buy
- Shares
- 35,714
- Amount
- $974K
- Trade date
- Oct 22, 2026
- Filed
- Oct 22, 2026, 0 days after the trade
- Source
- SEC Form 4
Six Rapport Therapeutics insiders have disclosed buying since Oct 21. At 08:31 ET the stock traded at $27.54, 8.7% above the previous close of $25.33.
Steven M Paul bought 35,714 shares at $27.28 on Oct 22. John Maraganore bought 9,411 shares at $26.45 the same day, and Chief Financial Officer Troy A. Ignelzi bought 5,500 shares at $26.10 on Oct 21. Our data has 3 more purchases in the last 90 days.
Against the first close after the purchase by Steven M Paul ($25.93 on Oct 23), the share is up 6.2%. The price is delayed by 15 to 20 minutes.
RAPP +3.5% on the day, close Oct 30
Today+8.7%At 08:31 ET, delayed
Price$27.54Previous close $25.33
Disclosed buys6In the last 90 days
Since purchase+6.2%Paul Steven M, Oct 22
The filing
Steven M PaulRapport Therapeutics, Inc.Buy35,714 sh · $974KTraded Oct 22, 2026 · Filed Oct 22, 2026 (0 days)SEC Form 4